Shaklee divested
This article was originally published in The Tan Sheet
Executive Summary
Yamanouchi Pharmaceuticals unloads subsidiaries Shaklee, Shaklee Japan and Inobys to New York-based private equity firms Activated Holdings and RHJ Industrial Partners for $310 mil., Yamanouchi announces April 2. The Tokyo-based pharmaceutical company is divesting its consumer holdings in order to focus on its core prescription business as it plans to merge with Fujisawa Pharmaceuticals (1"The Tan Sheet" March 15, 2004, p. 14)...
You may also be interested in...
Daiichi/Sankyo Merger Leaves Future Of OTC Unit Up In The Air
Daiichi's planned merger with Sankyo may lead to a divestiture of the former's OTC drug business
Shaklee Draws Private Investor Bid As Yamanouchi Plans Merger
Yamanouchi Pharmaceuticals subsidiaries Shaklee and Bear Creek Corp. are the subject of a $750 mil. blind bid by a group of private investors
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.